Share on StockTwits
 

Illumina (NASDAQ:ILMN) released its earnings data on Tuesday. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.44 by $0.01, Analyst Ratings News reports. The company had revenue of $387.00 million for the quarter, compared to the consensus estimate of $382.06 million.

Shares of Illumina (NASDAQ:ILMN) traded up 3.05% during mid-day trading on Tuesday, hitting $144.53. 3,570,546 shares of the company’s stock traded hands. Illumina has a one year low of $48.00 and a one year high of $148.48. The stock’s 50-day moving average is $114.8 and its 200-day moving average is $91.78. The company has a market cap of $18.268 billion and a price-to-earnings ratio of 167.36.

In other Illumina news, CEO Jay Flatley sold 30,000 shares of Illumina stock on the open market in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $142.30, for a total value of $4,269,000.00. Following the transaction, the chief executive officer now directly owns 399,509 shares in the company, valued at approximately $56,850,131. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

A number of research firms have recently commented on ILMN. Analysts at Leerink Swann raised their price target on shares of Illumina from $110.00 to $140.00 in a research note to investors on Friday, January 17th. On the ratings front, analysts at Bank of America Corp. raised their price target on shares of Illumina from $125.00 to $165.00 in a research note to investors on Friday, January 17th. Finally, analysts at Robert W. Baird raised their price target on shares of Illumina from $87.00 to $137.00 in a research note to investors on Friday, January 17th. Seven investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $113.11.

Illumina, Inc (NASDAQ:ILMN) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.